Skip to main content
Premium Trial:

Request an Annual Quote

Indivumed, Ultivue Sign Deal to Integrate Cancer Tissue Analysis Technologies

NEW YORK — Indivumed and Ultivue said on Wednesday that they have agreed to combine certain of their technologies into an offering for personalized cancer drug development.

Under the terms of the deal, the companies will join Indivumed's collection of standardized tissue biospecimens and immunohistochemistry (IHC) expertise with Ultivue's InSituPlex platform for high-throughput multiplex immunofluorescence.

Additional terms were not disclosed.

"By bringing Ultivue's technology and expertise into our workflow, we're giving our customers access to the contextual profiling of key cellular phenotypes," Indivumed Founder and CEO Hartmut Juhl said in a statement. "The data that can now be extracted from these valuable assets in our repository can support the full characterization of samples for biomarker and target discovery, drug development, clinical trials, and individualized therapy research. It will complete our offer in combination with the existing broad menu of IHC assays and end-to-end service."

In April, Hamburg, Germany-based Indivumed signed an agreement to integrate its IndivuType multiomic cancer database with genome and transcriptome-level data collected for samples collected using Personalis' advanced cancer genomics technology. 

In July, Cambridge, Massachusetts-based Ultivue began collaborating with OracleBio on an end-to-end workflow for tissue-based biomarker analysis.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.